Tag: Diabetes Management

Edwards Health Care Services, a GEMCORE Family Company, Recognized Among Cleveland’s Fastest-Growing Companies on Crain’s Cleveland Business “Fast 50” List

Edwards Health Care Services, a GEMCORE Family Company, Recognized Among Cleveland’s Fastest-Growing Companies on Crain’s Cleveland Business “Fast 50” List

December 16, 2024

Edwards Health Care Services, a GEMCORE family company, is proud to announce its inclusion on the prestigious “Fast 50” list published by Crain’s Cleveland Business. This annual list highlights the 50 fastest-growing privately held companies in Northeast Ohio, showcasing exceptional revenue growth over the past five years.

CRAIN's Cleveland Business Fast 50

Earning a place on Crain’s Fast 50 is a testament to the dedication of our incredible team and the trust our customers place in us. Our growth reflects our unwavering commitment to innovation, quality, and improving the lives of patients. We’re deeply honored by this recognition and look forward to building on this momentum in the years ahead.

– Matt Edwards, CEO

GEMCORE is a recognized leader in diabetes management solutions, offering comprehensive services including mail-order diabetes supplies, wholesale medical products, medications, specialized third-party logistics, and personalized health coaching. Together, these value-driven solutions reduce healthcare costs, enhance operational efficiencies, and improve patient outcomes. Headquartered in Hudson, Ohio, GEMCORE’s family of companies includes Edwards Health Care Services, GEMCO Medical, GemCare Wellness, and GEM Edwards Pharmacy.

Ranked 19th on the “Fast 50” list, GEMCORE employs over 300 people locally and continues to expand its impact in the healthcare and logistics sectors.

Crain’s Cleveland Business’s Fast 50 celebrates the fastest-growing privately held companies in Northeast Ohio based on revenue growth over the previous five years. The winning companies were founded on or before Dec. 31, 2017, and had at least $5 million in revenue in 2023, showing consistent year-over-year growth.

To learn more about the Crain’s Fast 50 list and read about the winners, visit www.crainscleveland.com.

###

Tags: ,

Related Articles

Where You Get Your CGM Matters

Where you get your CGM matters: Why choosing a company like EHCS can boost success

Using a Continuous Glucose Monitoring (CGM) system helps you manage diabetes by tracking your glucose levels throughout the day, which can help you stay in control and increase your time in range. A recent study found that patients who get their CGMs through a Durable Medical Equipment (DME) provider like Edwards Health Care Services (EHCS), instead of a pharmacy, are more likely to use them consistently. Why? Some DMEs – like EHCS – offer better support, personalized experiences, and assistance with insurance claims, making it easier for you to stay on track. Plus, better CGM usage means fewer health issues and lower overall costs for you.

where you get your CGM matters

The Role of CGMs in Diabetes Care

CGMs are invaluable tools for people with diabetes, providing near-constant feedback on glucose levels and reducing the need for fingerstick testing. These devices help you and your healthcare team to make timely, data-driven decisions, improving overall health outcomes. The adoption of CGM devices has been a game-changer, particularly for individuals with Type 1 diabetes and those managing insulin-dependent Type 2 diabetes.

We cannot stress enough how important it is for you to follow your doctor’s treatment regimen, including the use of your CGM. Higher adherence leads to better glucose control, fewer complications, and a reduced risk of hypoglycemia. And surprisingly, where you get your CGM – through a pharmacy or a DME like EHCS – can significantly impact your adherence and healthcare costs.

Key Findings from the Study: Pharmacy vs. DME Sourcing

A recent study, “Exploring the Impact of Device Sourcing on Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients With Diabetes,” revealed several important findings related to how CGMs are sourced:

  1. Better Adherence with DME Suppliers: The study found that patients who sourced their CGMs through DME suppliers were more likely to maintain consistent use of their devices. These patients also demonstrated higher rates of resuming therapy if they had experienced a lapse in usage. The structured support and education that often come with using a DME supplier may explain this improved adherence.
  2. Lower Overall Healthcare Costs: While the upfront costs of obtaining a CGM might be similar across pharmacies and DMEs, the study highlighted that DME-sourced patients incurred lower long-term healthcare costs. The improved adherence observed in the DME group likely contributes to this, as better glucose control leads to fewer diabetes-related complications, emergency room visits, and hospitalizations.
  3. Better Continuity of Therapy: Patients using DMEs like EHCS were more likely to continue CGM therapy after an interruption. This could be attributed to the personalized support provided by DME suppliers, which ensures patients are more informed and equipped to use their CGMs effectively.

Ready to get started?

ENROLL TODAY

Why DME Sourcing Works Better for CGM Users

Why you should get a CGM from a DME

For many patients, the choice between sourcing a CGM device from a pharmacy or a DME supplier may seem like a simple logistical decision, but it can have profound implications on adherence and outcomes. Here are a few reasons why sourcing through a DME supplier often leads to better results:

  • Personalized Support and Onboarding: For more than 30 years, EHCS has been working with patients, their healthcare teams, and insurance plans to provide the best products for effective diabetes therapy. DME suppliers like EHCS can offer more personalized guidance, from setting up your account and using your CGM to managing reorders, so you never run out of supplies.
  • Comprehensive Insurance Navigation: With decades of experience navigating insurance claims and approvals, EHCS is well-suited to help patients access the devices they need with minimal hassle. This seamless process can reduce interruptions in therapy and ensure that patients continue to use their devices regularly.
  • Higher Quality of Education: DMEs typically provide more in-depth education on how to maximize the benefits of a CGM. We have close relationships with the manufacturers, and we are trained on products from the beginning and work with you to ensure you receive the right training. We’ve found that proper education is critical to adherence because if you understand how the device works and how to interpret the data, you’re more likely to use it consistently.

The Value of DME in CGM Therapy

For patients with diabetes, the use of continuous glucose monitoring devices can be life-changing. As this study shows, where and how patients obtain these devices matters significantly. DME suppliers like EHCS are uniquely positioned to support higher adherence rates, better glucose control, and lower healthcare costs, offering clear advantages over pharmacy-based sourcing.

By choosing EHCS, you’re more likely to stick with your CGM therapy, avoid gaps in usage, and experience better health outcomes. If you ever have questions or need assistance with your CGM, we are here to help!

For more insights into the study, you can access the full text here: https://pubmed.ncbi.nlm.nih.gov/38804821. If you’re ready to receive your CGM supplies from EHCS, you can click the button below to get started, call us at 1.800.951.1725, or email our Diabetes Care team at dca@myehcs.com.

Ready to get started?

ENROLL TODAY
Tags: ,

Related Articles

Direct to Watch Now Available with Dexcom G7

Direct to Watch Now Available with Dexcom G7

June 07, 2024

The Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch!* This update makes it even easier for people living with diabetes to keep an eye on their glucose numbers. Dexcom is excited about this latest CGM innovation and is the first and currently only brand to offer this feature.

Dexcom G7 and Sensor with Apple Watch
https://myehcs.com/wp-content/uploads/Dexcom_DTW.png

  • UNMATCHED FREEDOM AND CONVENIENCE: The sensor can now connect directly to Apple Watch,* so there’s no need to carry an iPhone to check glucose numbers.†

  • GLUCOSE NUMBERS ON THREE DEVICES: Only Dexcom G7 can display real-time glucose data on a smartphone, smartwatch,* receiver, or connected automated insulin delivery (AID) system,‡ independent of each other.

  • ABILITY TO ACKNOWLEDGE ALERTS FROM APPLE WATCH: With Direct to Apple Watch connectivity, users can receive and acknowledge their CGM alerts via their Apple Watch independent of their iPhone.†

  • ENHANCED DISCRETION: Users can see their glucose numbers in real time and know if they’re rising or falling with a quick glance at their wrist.

Dexcom continuous glucose monitoring is available from Edwards Health Care Services. Many insurance plans, including Medicare, covers CGM technology for eligible members. Apply online for your Dexcom G7 today!

Apply for a Dexcom G7 Today!

Apply Now

* Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility.
† Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 20 feet of the Dexcom G7.
‡ To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/integrate.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Tags: , , , ,

Related Articles

What is Insulin Pump Therapy?

What is Insulin Pump Therapy?

February 29, 2024

A Type 1 diabetes diagnosis brings the potential for lifelong challenges, including the constant need for insulin management, increased susceptibility to complications, and the emotional toll of living with a chronic condition.

Opting for insulin pump therapy provides a secure and straightforward approach to enhance glucose control, offering a proactive solution for managing diabetes effectively.

insulin pump therapy

Choosing insulin pump therapy presents a reliable and uncomplicated method to improve control over glucose levels, providing a proactive and efficient solution for the effective management of diabetes.

What is insulin pump therapy?

What is insulin pump therapy, and what is an insulin pump?

An insulin pump is a small electronic device that delivers insulin continuously. It’s a valuable tool for individuals with Type 1 diabetes who require insulin therapy. The device consists of three main components: an insulin reservoir, a pump mechanism, and a catheter that delivers the insulin into your body. It’s designed to mimic the functioning of a healthy pancreas.

The pump delivers insulin through a small tube, known as a catheter, which is inserted under the skin. The placement of the catheter is flexible, allowing you to rotate the infusion site and minimize the risk of irritation. The pump can deliver different basal rates throughout the day, adjusted to match your specific insulin needs. It can also deliver bolus doses of insulin to cover meals or correct high blood sugar levels.

Using an insulin pump requires regular monitoring and adjustments. It’s important to work closely with your healthcare team to ensure proper pump management and achieve optimal results.

Apply for an insulin pump from EHCS

Apply Today

Benefits of Using an Insulin Pump

Insulin pump therapy provides numerous benefits for individuals with type 1 diabetes. These include improved blood sugar control and A1C levels, flexibility in meal planning and physical activities, and a reduced risk of hypoglycemia. EHCS offers a range of insulin pump options designed to meet your specific needs. Our expert team can guide you through the process of choosing the right pump and provide comprehensive support to ensure a seamless transition to insulin pump therapy.

  • Delivers insulin accurately and often improves your A1C

  • Eliminates individual insulin injections

  • Allows flexibility about what and you eat, making diabetes management easier

  • Eliminates unpredictable effects of intermediate or long acting insulin

Is Insulin Pump Therapy Right For You?

Insulin pump therapy is a valuable treatment option for individuals with type 1 diabetes seeking better blood sugar control and improved quality of life. This technology offers a convenient and efficient way to deliver insulin, reducing the need for multiple daily injections. Whether you’re an adult or a child, insulin pump therapy can greatly benefit you. It provides improved glycemic control, precise insulin dosing, and simplifies insulin administration, making it easier to incorporate diabetes management into daily life.

Our team is ready to help you get started! We offer a range of insulin pumps and are committed to helping improve your quality of life living with diabetes. Once you’ve completed our online application, we will work with you, your doctor, and insurance company to help you get the insulin pump and supplies you need. If you have any questions, please reach out to our Diabetes Care team at DCA@myehcs.com.

EHCS Works With Medicare, Medicaid, And Most Commercial Insurance Plans Nationwide! We Are Dedicated To Continuously Expanding Our Reach.

Have you been approved for an insulin pump?

Apply Today
Tags: , , ,

Related Articles

Upgrade Your MiniMed™ 770G to the 780G Software

Upgrade Your MiniMed™ 770G to the 780G Software

February 19, 2024

If you have a Medtronic MiniMed™ 770G pump, you are eligible for a no-cost software upgrade to the MiniMed™ 780G pump until April 27, 2024. Unlocking this advanced technology from Medtronic can help you have the confidence to navigate your unique diabetes journey.

MiniMed 780G from Medtronic

Real-time insulin adjustments and corrections† all day and night

With this software upgrade, you’ll have access to the new Guardian™ 4 sensor, providing you with:

  • Meal Detection™ technology that detects if you’ve accidentally missed a dose* or undercounted carbs and automatically delivers correction† boluses of insulin, as often as every 5 minutes§
  • The ability to set your Glucose targetΔ as low as 100 mg/dL

Your no-cost software upgrade is available until April 27, 2024, so don’t delay — start your upgrade today!

Please note: If you still have Guardian™ 3 sensors, you can use them with your upgraded pump, but you will have to do fingersticks at least 2 times a day.

https://myehcs.com/wp-content/uploads/MED-770G-780G-Comparison.png

Start Your Software Upgrade Today!

Go to Diabetes.shop

How to Initiate a Software Upgrade from the MiniMed™ 770G pump to the MiniMed™ 780G pump

  1. Place your order on Diabetes.shop for the software upgrade and compatible continuous glucose monitor (CGM) sensor. If you don’t already have an online account, you will need to create one.
  2. Obtain a prescription: Medtronic will obtain a prescription from your healthcare provider for the MiniMed™ 780G pump and compatible CGM sensor.
  3. Review software upgrade kit: Medtronic will ship you software upgrade resources and pump instructions for use.
  4. Complete the required online training: Sign in to Diabetes.shop to watch the required training videos that will take about 40 minutes to complete. Once complete, Medtronic will send you an email within 72 hours to let you know your upgrade is available.
  5. Download the Medtronic Diabetes Updater app: Install the Medtronic Diabetes Updater app on a compatible phone. Available on Apple and Google Play app stores.
  6. Upgrade your pump software to the MiniMed™ 780G pump: Follow the step-by-step instructions on the updater app, including signing into your CareLink™ Personal account. You can wear your pump during most of the two-and-a-half-hour upgrade period. Interaction is required during this time. You are finished when you reach “Software Update Successful” on your phone.

FOOTNOTES
*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
†Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
§Refers to SmartGuard™ feature. Individual results may vary.
Δ Glucose targets should be set following a consultation with your healthcare provider.
Ω Fingersticks required in manual mode and to enter SmartGuard™. If symptoms don’t match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard™.
Φ Smart devices sold separately. For a list of compatible devices, visit http://bit.ly/CheckDevices.

MINIMED™ SYSTEM SOFTWARE UPGRADE PROGRAM
This program allows MiniMed™ 770G system users a software upgrade at no charge until April 27, 2024.
•   Software upgrade process is subject to change. The process may result in a healthcare provider office visit and may result in out-of-pocket expenses such as co-pay, depending on insurance coverage. The process may require the completion of product related training.
•   This program includes the insulin pump software only. CGM products and consumables are not included in this offer.
•   Warranty dates do not reset. The replacement warranty date of an insulin pump upgraded with the software will remain the same as the replacement warranty date of the initial pump purchased. Your warranty date does not impact eligibility for a software update.
•   MiniMed™ pumps and software have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding your eligibility to receive the software upgrade based on the labeling of the upgrade, which may differ from the labeling of the MiniMed™ 770G pump.
•   Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply.
•   A valid prescription will be required for this software upgrade. All participants should consult their healthcare provider for all therapy related decisions.
•   Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.

IMPORTANT SAFETY INFORMATION

Medtronic MiniMed™ 780G System With SmartGuard™ Technology with Guardian™ 4 Sensor

The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed™ 780G system consists of the following devices: MiniMed™ 780G insulin pump, the Guardian™ 4 transmitter, the Guardian™ 4 sensor, One press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian™ 4 sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a p rescrip tion . The Guardian™ 4 sensor is indicated for up to seven days of continuous use.

The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.

WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Tags: , , , , ,

Related Articles

MiniMed 780G from Medtronic

MiniMed 780G from Medtronic

December 12, 2023

The MiniMed™ 780G Insulin Pump system is designed for real life. Ever miss a meal dose sometimes or underestimate a carb count? Life with diabetes can be unpredictable. Now there’s an insulin pump system designed with Meal Detection™ technology* that automatically adjusts and corrects† sugar levels every 5 minutes§.

MiniMed 780G from Medtronic

Helping you Manage Sugar Levels with Real-Time Insights!

The MiniMed™ 780G system gives you greater freedom and peace of mind with real-time adjustments and corrections† every five minutes all day and night§. Powered by advanced SmartGuard™ technology, this system:

  • Anticipates insulin needs based on real-time sugar trends
  • Adjusts insulin delivery to help smooth out highs and lows
  • Corrects† highs automatically§ to help cover underestimated carb counts and an occasionally missed meal dose3


What is meal detection* and how does it work?

The system uses current and past sugar trends to detect a missed meal dose.* If the system detects sugar levels rising it can automatically deliver a stronger correction dose for undercounted carbs every five minutes to help prevent highs.§

.

Ready to get started?

Apply Today

References
*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
§ Refers to SmartGuard™ feature. Individual results may vary.
† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
3. Matejko B. et al, Diabetes Care. 2022;https://doi.org/10.2337/dc220470.

Important safety information: MiniMed™ 780G system with SmartGuard™ technology with Guardian™ 4 sensor

The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed™ 780G system consists of the following devices: MiniMed™ 780G insulin pump, the Guardian™ 4 transmitter, the Guardian™ 4 sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian™ 4 sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ 4 sensor is indicated for up to seven days of continuous use.

The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.

WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Tags: , , , , ,

Related Articles

GEMCORE Recognized Once Again as a Top Workplaces Winner

GEMCORE Recognized Once Again as a Top Workplaces Winner

June 26, 2023

GEMCORE, a family of companies, has been awarded a Top Workplaces 2024 honor by The Plain Dealer and Cleveland.com, the Cleveland metro area newspaper. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization including alignment, execution, and connection, to name a few

Top Workplace

We are deeply honored by GEMCORE’s fifth consecutive appearance on The Cleveland Plain Dealer Top Workplaces list. This ongoing achievement reflects the unwavering dedication of our exceptional team, who consistently go above and beyond in serving our organization and our customers living with chronic health conditions. We are thrilled to be recognized with this prestigious honor once again.

– Matt Edwards, CEO

With its four divisions — Edwards Health Care Services, GEMCO Medical, GemCare Wellness, and GEM Edwards Pharmacy — GEMCORE proudly offers a comprehensive suite of value-driven diabetes management solutions designed to lower healthcare costs, enhance efficiencies, and improve patients’ lives. The company employs over 260 dedicated professionals at its local headquarters and was ranked 19 in the Midsize Companies category. For the complete list of 2024 Top Workplace Winners, click here.

The Plain Dealer’s Top Workplaces list continues to reflect companies in the region that cultivate a connection with their workforce. This year’s Workplaces list ranks 433 companies, nonprofits, schools, and other employers. These organizations share a commitment to providing support and an environment that makes employees feel valued and respected.

Tags: ,

Related Articles

Why Should I Get a CGM?

Why Should I Get a CGM?

February 20, 2023

While today’s glucose meters make things much easier, it can still be a pain to constantly check your blood sugar. What if you had a way to continuously monitor your blood glucose without getting out your meter and test strips all the time? And what if you (or your loved ones) could be alerted to changes? That’s what “continuous glucose monitoring” – or CGM – is all about.

Why should I get a CGM, and what is continuous glucose monitoring? Find out how to get a CGM from EHCS.

When you really look at what continuous glucose monitoring (CGM) is all about, it becomes clear why so many people tout their importance in managing their diabetes. First let’s start with defining CGM: A CGM is a small, wearable device that tracks glucose throughout the day and night, notifying you of highs and lows so you can, if needed, act immediately. CGM minimizes the guesswork for better diabetes management. The CGM is made of a sensor and a receiver. The flexible sensor (smaller than a syringe) goes into your skin every couple of weeks, and once it’s in, you won’t feel a thing. The receiver is smaller than a smartphone and lets you see what’s going on with a nifty graph. CGMs often connect to smartphones and tables so that you can access and share info in real-time (this is great for a loved one whose blood sugar you need to monitor regularly). Dexcom created the video below to explain how CGM therapy works:

Why Order From EHCS?

Learn More About Us

What is Continuous Glucose Monitoring?

Continuous glucose monitoring gives you a complete picture of your glucose, showing you where it is going and how fast it’s getting there. People who use a CGM as part of their diabetes management find that CGMs:

  • Can help lower A1C in adults 25+ with type 1 diabetes (when used with insulin regimens, according to a public comment and response by the Washington State Healthcare Authority)

  • Read glucose regularly, which allows the wearer to keep an eye on glucose, catching highs and lows more quickly and identifying trends

  • Alert the wearer to highs and lows more quickly so you can make changes quickly

  • Track data better, which makes life easier for wearers, doctors, parents, etc.

  • Provide better insight into how lifestyle affects diabetes management

While CGM is most often used for people with Type 1 diabetes, many people (especially those using insulin) will find a CGM helpful in managing diabetes. In fact, a recent study conducted at the University of British Columbia found that a CGM helped people with Type 2 diabetes and prediabetes stick to an exercise plan, which helps control their health.

How to get a CGM

Now it’s easy to get started! Just fill out this enrollment form, and our Diabetes Care Advisors (DCAs) will help you with every step of the insurance process. We carry CGMs from the major manufacturers including the Abbott FreeStyle Libre systems, the Dexcom G6 and G7 systems, and the Medtronic Guardian Connect. We work with hundreds of insurances, including Medicare, that cover CGM therapy for those who qualify. Your DCA will determine your benefits and then act on your behalf throughout the insurance authorization process. We will work with you and your healthcare team to ensure you received the best product suited for your specific needs.

For additional information on insurance plans that EHCS accepts, call us at 1-888-344-3434 or email us at dca@myehcs.com. If you’re ready to find out if your insurance covers a CGM, fill out the enrollment form and we’ll get the process started.

Tags: , , , ,

Related Articles

Parent Company of Edwards Health Care Services Honored for a Third Time as a Weatherhead 100 Centurion Award for Driving Leadership, Growth, and Success in Northeast Ohio

Parent Company of Edwards Health Care Services Honored for a Third Time as a Weatherhead 100 Centurion Award for Driving Leadership, Growth, and Success in Northeast Ohio

December 13, 2022

GEMCORE, a family of companies, has been named a Weatherhead 100 Centurion company for a third consecutive time by Case Western Reserve University’s Weatherhead School of Management.

An industry leader in diabetes management solutions, GEMCORE provides mail-order diabetes supplies and and medications; health and wellness coaching and chronic disease management; and wholesale distribution and third-party logistics services tailored to the clients it serves.

Weatherhead Centurion Award

It’s truly an honor to receive the Weatherhead Centurion recognition. Our continued growth is a testament to our steadfast commitment and passion for helping people with chronic conditions live better and healthier lives. We are thrilled to be a part of a list of impressive companies in the community.

-Matt Edwards, CEO

Its subsidiaries include Edwards Health Care Services, GEMCO Medical, GemCare Wellness, and GEM Edwards Pharmacy.

The Weatherhead 100 awards program recognizes fast-growing companies in Northeast Ohio that are the best examples of leadership, growth, and success in the region. Winners are chosen based on percent of revenue growth over the past five years, with the Centurion award recognizing a select group of the region’s top revenue-generating companies.

Founded in 1992 as a mail-order supply company out of the Edwards family home, GEMCORE has since grown to more than 350 employees at its main headquarters in Hudson, Ohio, and across eight branch locations throughout the U.S. In 2020, the company embarked on its third major facilities expansion, adding an additional 50,000 square feet to its state-of-the-art distribution center to support the growth of its 3PL medical fulfillment service, which launched in 2018.

The Weatherhead recognition joins a growing list of recent accolades for the company, including the 2022 Cleveland Plain Dealer Top Workplace and the 2022 Inc. 5000 Fastest-Growing Companies list.

Tags: ,

Related Articles

Rising to the Challenge, 2022 Inc 5000 List

Rising to the Challenge, 2022 Inc 5000 List

August 22, 2022

GEMCORE, a family of companies, has again been named one of the fastest-growing private companies in America by Inc. Magazine, earning the rank of No. 3,751 on the 2022 Inc. 5000 list. The companies on the 2022 Inc. 5000 list have not only been successful but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of Covid-19.

Inc 5000 America's Fastest-Growing Private Companies

We’re thrilled to be recognized by Inc. Magazine once again. It’s quite an honor, and we’re immensely proud of our team for their hard work and rising to the challenges we’ve seen over the past couple of years.

-Matt Edwards, CEO

This is the third consecutive year GEMCORE has been recognized. Not only have the companies on the 2022 Inc. 5000 been very competitive within their markets, but the list shows staggering growth compared with prior lists. Complete results of the Inc. 5000, including company profiles, can be found at www.inc.com/inc5000.

GEMCORE is an industry leader in diabetes management solutions, providing mail-order diabetes supplies, wholesale medical supplies, medications, third-party logistics, and health coaching and disease management services for its clients. Its subsidiaries include Edwards Health Care Services, GEMCO Medical, GemCare Wellness, and GEM Edwards Pharmacy.

To learn more about GEMCORE and its services, please visit www.gemcorehealth.com.

Tags: ,

Related Articles

Upgrade Your Medtronic Pump Before Your Benefits Reset!

Contact Us: 1.888.344.3434

Home          Shop Breast Pumps          Support for Moms          FAQs          Why Choose EHCS          Store         

Upgrade Your Medtronic Pump Before Your Benefits Reset!

August 18, 2022

The MiniMed™ 770G insulin pump system automatically adjusts background insulin every 5 minutes.** Using real-time glucose readings, the system is able to calculate a personalized amount of insulin to deliver based on CGM.

upgrade your medtronic pump

This post refers to an older Medtronic insulin pump. Click here to learn about the latest technology in Medtronic insulin delivery with the MiniMed 780G. 

Medtronic MiniMed™ 770G™ Insulin Pump System

The Medtronic MiniMed™ 770G™ insulin pump system is the technology that adapts to you! Approved for ages 2 and up, this new, FDA-approved system connects directly with a compatible smartphone, allowing you to view sugar trends and insulin delivery on the go.

Are you Eligible to Upgrade your Insulin Pump?

UPGRADE TODAY!

Ready to upgrade your Medtronic pump?

The MiniMed™ 770G™ system gives you the flexibility to continue living your life while managing your diabetes! Sometimes referred to as a hybrid closed loop system, it automatically adjusts delivery of basal (background) insulin based on CGM sensor glucose values. This means that the pump gets glucose readings from the CGM automatically, and then delivers a variable rate of insulin 24 hours a day based on your personal needs.** This integrated system – meaning having a pump and a CGM that speak to one another – may help reduce both high and low glucose levels.**

You can even stay up-to-date on your glucose trends and insulin delivery 24/7 using the MiniMed™ Mobile app for iOS and Android. This system adapts to your unique needs, so you can focus on living your life and worrying less about managing your diabetes!

Multiple Features Make Managing Your Diabetes Easier:

  • Data-sharing capability makes virtual and in-person doctor’s appointments easier

  • Smartguard™ Auto Mode helps prevent glucose highs and lows

  • MiniMed™ Mobile App allows you to discreetly check your numbers

  • Carelink™ Connect App brings more peace of mind for care partners

  • Exercise setting may reduce lows during activities

Now may be the best time to upgrade to the 770G system, and get access to Medtronic’s MiniMed™ 780G* software upgrade at no cost, when available. Software upgrades provide the latest pump features without having to switch your physical pump!

*Investigational. Not approved by the FDA for any use and not commercially available in the US. We will let you know as soon as the software upgrade is available with the option to add our future CGM!

**Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.

IMPORTANT SAFETY INFORMATION: MINIMED™ 770G SYSTEM WITH SMARTGUARD™ TECHNOLOGY

The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu- Chek®Guide Test Strips. The system requires a prescription.

The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).

All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.

WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety- information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library. 

Tags: , , , , , , ,

Related Articles

Putting Customer First, 2022 Top Workplaces

Putting Customer First, 2022 Top Workplaces

June 27, 2022

GEMCORE, a family of companies, has been awarded a Top Workplaces 2022 honor by The Plain Dealer, the major newspaper for the Cleveland metro area. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization, including alignment, execution, and connection.

top workplace 2022

GEMCORE is dedicated to building a workplace culture that rewards and empowers employees who share our mission to improve customers’ lives through our innovative healthcare products and services. Our third appearance on The Cleveland Plain Dealer Top Workplaces is a testament to the entire team’s commitment to our mission and those customers we serve daily.

-Matt Edwards, CEO

Through its four divisions — Edwards Health Care Services, GEMCO Medical, GemCare Wellness, and GEM Edwards Pharmacy — GEMCORE employs more than 300 people locally and was ranked 23rd in the Midsize Companies category. For the complete list of 2022 Top Workplace Winners, click here.

“GEMCORE is dedicated to building a workplace culture that rewards and empowers employees who share our mission to improve customers’ lives through our innovative healthcare products and services. Our third appearance on The Cleveland Plain Dealer Top Workplaces is a testament to the entire team’s commitment to our mission and those customers we serve daily,” said Matthew Edwards, GEMCORE’s CEO. “We are thrilled to be recognized with this honor once again.”

The Plain Dealer’s Top Workplaces list continues to reflect companies in the region that cultivate a connection with their workforce. This year’s Workplaces list ranks 406 companies, nonprofits, schools, and other employers. These organizations share a commitment to providing support and an environment that makes employees feel valued and respected.

Tags: ,

Related Articles

Your Cart